These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 2507775)
1. Anti-ischemic effects of the potassium channel activators pinacidil and cromakalim and the reversal of these effects with the potassium channel blocker glyburide. Grover GJ; McCullough JR; Henry DE; Conder ML; Sleph PG J Pharmacol Exp Ther; 1989 Oct; 251(1):98-104. PubMed ID: 2507775 [TBL] [Abstract][Full Text] [Related]
2. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents. Sargent CA; Smith MA; Dzwonczyk S; Sleph PG; Grover GJ J Pharmacol Exp Ther; 1991 Oct; 259(1):97-103. PubMed ID: 1920138 [TBL] [Abstract][Full Text] [Related]
3. KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide. Ferdinandy P; Szilvássy Z; Droy-Lefaix MT; Tarrade T; Koltai M Cardiovasc Res; 1995 Nov; 30(5):781-7. PubMed ID: 8595627 [TBL] [Abstract][Full Text] [Related]
4. Potassium channel openers and blockers: do they possess proarrhythmic or antiarrhythmic activity in ischemic and reperfused rat hearts? Tosaki A; Szerdahelyi P; Engelman RM; Das DK J Pharmacol Exp Ther; 1993 Dec; 267(3):1355-62. PubMed ID: 8263798 [TBL] [Abstract][Full Text] [Related]
6. Comparison of effects of cromakalim and pinacidil on mechanical activity and 86Rb efflux in dog coronary arteries. Masuzawa K; Asano M; Matsuda T; Imaizumi Y; Watanabe M J Pharmacol Exp Ther; 1990 May; 253(2):586-93. PubMed ID: 2160002 [TBL] [Abstract][Full Text] [Related]
7. The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanism. Grover GJ; D'Alonzo AJ; Sleph PG; Dzwonczyk S; Hess TA; Darbenzio RB J Pharmacol Exp Ther; 1994 May; 269(2):536-40. PubMed ID: 8182522 [TBL] [Abstract][Full Text] [Related]
8. Alterations by glyburide of effects of BRL 34915 and P 1060 on contraction, 86Rb efflux and the maxi-K+ channel in rat portal vein. Hu SL; Kim HS; Okolie P; Weiss GB J Pharmacol Exp Ther; 1990 May; 253(2):771-7. PubMed ID: 2110977 [TBL] [Abstract][Full Text] [Related]
9. Comparative effects of the K+ channel openers, pinacidil and cromakalim on vascular tone: sensitivity to glyburide and calcium. Triggle CR; Li YQ; Wyse DG Proc West Pharmacol Soc; 1992; 35():97-102. PubMed ID: 1502246 [No Abstract] [Full Text] [Related]
10. Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate. McCullough JR; Normandin DE; Conder ML; Sleph PG; Dzwonczyk S; Grover GJ Circ Res; 1991 Oct; 69(4):949-58. PubMed ID: 1934346 [TBL] [Abstract][Full Text] [Related]
11. Cardioprotective effects of a novel calcium antagonist related to the structure of cromakalim. Grover GJ; Sleph PG; Dzwonczyk S; McCullough JR J Pharmacol Exp Ther; 1993 Oct; 267(1):102-7. PubMed ID: 8229736 [TBL] [Abstract][Full Text] [Related]
12. Cardioprotective effects of the potassium channel opener cromakalim: stereoselectivity and effects on myocardial adenine nucleotides. Grover GJ; Newburger J; Sleph PG; Dzwonczyk S; Taylor SC; Ahmed SZ; Atwal KS J Pharmacol Exp Ther; 1991 Apr; 257(1):156-62. PubMed ID: 2019983 [TBL] [Abstract][Full Text] [Related]
13. Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies. Docherty JC; Gunter HE; Kuzio B; Shoemaker L; Yang L; Deslauriers R J Mol Cell Cardiol; 1997 Jun; 29(6):1665-73. PubMed ID: 9220352 [TBL] [Abstract][Full Text] [Related]
14. Comparative effects of the potassium channel openers cromakalim and pinacidil and the cromakalim analog U-89232 on isolated vascular and cardiac tissue. Norman NR; Toombs CF; Khan SA; Buchanan LV; Cimini MG; Gibson JK; Meisheri KD; Shebuski RJ Pharmacology; 1994 Aug; 49(2):86-95. PubMed ID: 7972325 [TBL] [Abstract][Full Text] [Related]
15. The ATP-sensitive potassium channel blocker glibenclamide (glyburide) does not abolish preconditioning in isolated ischemic rat hearts. Grover GJ; Dzwonczyk S; Sleph PG; Sargent CA J Pharmacol Exp Ther; 1993 May; 265(2):559-64. PubMed ID: 8496806 [TBL] [Abstract][Full Text] [Related]
16. Effect of timing of treatment of the glyburide-reversible cardioprotective activity of BMS-180448. Gomoll AW; Roth RA; Swillo RE; Baird AJ; Sargent CS; Behling RW; Malone HJ; Grover GJ J Pharmacol Exp Ther; 1997 Apr; 281(1):24-33. PubMed ID: 9103476 [TBL] [Abstract][Full Text] [Related]
17. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity. Grover GJ; D'Alonzo AJ; Garlid KD; Bajgar R; Lodge NJ; Sleph PG; Darbenzio RB; Hess TA; Smith MA; Paucek P; Atwal KS J Pharmacol Exp Ther; 2001 Jun; 297(3):1184-92. PubMed ID: 11356945 [TBL] [Abstract][Full Text] [Related]
18. Differential effects of diazoxide, cromakalim and pinacidil on adrenergic neurotransmission and 86Rb+ efflux in rat brain cortical slices. Takata Y; Shimada F; Kato H J Pharmacol Exp Ther; 1992 Dec; 263(3):1293-301. PubMed ID: 1469635 [TBL] [Abstract][Full Text] [Related]
19. Pharmacologic profile of cromakalim in the treatment of myocardial ischemia in isolated rat hearts and anesthetized dogs. Grover GJ; Sleph PG; Dzwonczyk S J Cardiovasc Pharmacol; 1990 Dec; 16(6):853-64. PubMed ID: 1704976 [TBL] [Abstract][Full Text] [Related]
20. Proarrhythmic effects of pinacidil are partially mediated through enhancement of catecholamine release in isolated perfused guinea-pig hearts. D'Alonzo AJ; Zhu JL; Darbenzio RB; Dorso CR; Grover GJ J Mol Cell Cardiol; 1998 Feb; 30(2):415-23. PubMed ID: 9515018 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]